SUMMARY Nifedipine, a calcium antagonist with strong vasodilatating effects, has been successfully used in the treatment of angina pectoris. To investigate if it can be used as a vasodilator in patients with congestive heart failure, nifedipine 20 mg was administered sublingually to 11 patients with chronic heart failure. The clinical diagnosis was congestive cardiomyopathy in 10 and severe mitral regurgitation in one patient. All patients were studied haemodynamically and in 10 of them an angiographic study was also performed.
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Nifedipine lowered mean systemic arterial pressure (from 95-0 5.3 to 75-2 43-6 mmHg), mean pulmonary arterial pressure (from 37-9±3-1 to 28-0±2t4 mmHg), mean pulmonary capillary wedge pressure (from 25-2 +20 to 16.7 ± 1.7 mmHg), left ventricular end-diastolic pressure (from 22-6 ± 1-8 to 14 2 i 1 7 mmHg), and systemic vascular resistance (from 1967 +247 to 1108 146 dynes s cm-5).
Simultaneously all indices of left ventricular performance improved: cardiac index rose from 2 12 ±01 1 to 3 11±0-301/M2 per min, ejection fraction increased from 0-26±0'02 to 0-41±+0-05 per cent, and stroke volume index rose from 32-2±1-9 to 46-8±3-4ml/m2. Left ventricular end-diastolic volume index and end-systolic volume index both diminished (from 137'2± 14-0 to 128-1 i 14-3 ml/m2 and from 104.9 ± 13.6 to 81'3 + 14-7 ml/m2, respectively). No significant changes in heart rate were noted, whereas a slight general improvement in left ventricular wall motion was seen.
In patients with congestive heart failure, there were no negative inotropic effects but an improvement in left ventricular performance in all patients, caused by a decrease in afterload secondary to the strong vasodilatating effect of the drug.
Further studies should document the possibility of nifedipine being used as an alternative to other afterload reducing agents in the chronic treatment of heart failure.
Systemic vasodilator drugs have been used increasingly during recent years in the treatment of heart failure.1-3 These agents decrease the oxygen consumption and enhance the performance of the failing heart,' by reducing left ventricular wall tension in systole (afterload) and/or decreasing systemic venous return.
Nifedipine is a drug with a calcium antagonist action which has proved to be particularly effective in the treatment of angina pectoris.5-7 The main actions of this drug in man are a reduction of peripheral resistance8 9 and an increase in coronary flow especially in post-stenotic areas.10 11
Considering its effects on the peripheral resistance vessels and the low incidence of side effects,'2 nifedipine may be useful as a vasodilator in the treatment of chronic heart failure. showed a change in mean right atrial pressure. The average decline was -21 per cent and was significant (p < 0-025). Pulmonary vascular resistance fell by an average of 40 per cent but this change was not significant. In the seven patients with high resistances ( > 120 dynes s cm-5), this fall was significant (Fig. 1) and was well correlated with the pretreatment values (Fig. 2) .
There was no significant change in heart rate: four patients had a small increase, and seven patients a small decrease in heart rate.
Angiographic results are shown in Table 3 . All patients showed an increase in stroke volume and ejection fraction (+45 and +57%, respectively) and a decrease in left ventricular end-systolic volume (-22%). Left ventricular end-diastolic volume decreased significantly (-6%), but in two patients (cases 7 and 10) showed a slight increase. Changes in segmental systolic shortening are shown in Fig. 3 . This effect (with the consequent reduction in left ventricular afterload) and the increase in coronary flow10 11 are the main mechanisms of action of this drug in ischaemic heart disease. The rapidity and efficacy of nifedipine mediated reduction of peripheral resistance,9 moreover, suggested that it might represent a first choice drug in hypertensive emergencies. '16 The negative inotropic action of nifedipine, initially described in the isolated heart muscle preparation,17 was not shown in the haemodynamic studies which followed in man. The Fig. 1 Change in pulmonary vascular resistance after mfedipine administration in the seven patients with high (> 120 dynes s cmnr5) resistance (mean ± SEM). Cases 1, 2, 6, 7, 9, 10, 11. B, basal; N, nifedipine.
pronounced vasodilatating effect, not accompanied by any change in contractility, may be explained by the in vitro observation that the excitation-contraction coupling of vascular smooth muscle is three to 10 times more sensitive than myocardial fibres to the action of calcium antagonist drugs.'8 The vasodilatating effect, therefore, can be achieved even at a dosage inadequate to act on myocardial contractility. In haemodynamic studies in man a slight increase in peak dP/dt has been observed in some subjects.9 16 19 This may be a result of the baroceptor mediated response to a fall in arterial pressure. In this study nifedipine was used to reduce impedance to ventricular emptying in a group of patients suffering from chronic congestive heart failure. In the group studied, nifedipine determined important haemodynamic changes (Table 2 ). There was a significant fall in mean pulmonary artery, mean aortic, and left ventricular end-diastolic pressure, a decrease in systemic vascular and total pulmonary resistance, and a significant increase in cardiac index. Angiographic derived data (Table 3) also showed an improvement in left ventricular performance, as evidenced by an increase in ejection fraction and stroke volume and a decrease in both left ventricular end-diastolic and end-systolic volumes. Segmental shortening analysis (Fig. 3 ) indicated a diffuse hypokinesis in all patients and showed a general but not statistically significant improvement. Nifedipine exerts in vitro a pronounced relaxation on vascular smooth muscle,'8 and this finding was subsequently confirmed in studies undertaken in man.9 16 It is likely, therefore, that afterload reduction, resulting from arteriolar vasodilatation, is responsible for the haemodynamic changes and the improvement in left ventricular performance observed in our patients. The fall in systemic vascular resistance was more pronounced in the patients with high initial resistance levels (Fig. 4) and this may suggest that nifedipine acts predominantly where arteriolar tone is higher. The effect of nifedipine on pulmonary vascular resistance is similar and consistent with this suggestion. A significant decrease took place only in the seven patients with high resistance (Fig. 1) and was well correlated with the initial resistance levels (Fig. 2) Previous and present data indicate that nifedipine is an active afterload reducing agent. Since nifedipine, in vitro, exerts a negative inotropic effect, it is thus likely that the observed increase in ejection fraction and stroke volume is secondary to the afterload reduction and not a direct inotropic effect on the heart. Nifedipine has already been used to treat hypertensive emergencies.'6 Present data suggest that it can also be safely used to provide a rapid and distinct ventricular unloading in patients with left ventricular failure and raised systemic vascular resistance. There are still several problems, however, concerning the use of nifedipine as an alternative to vasodilator drugs currently used for the long-term treatment of heart failure.
Further studies are needed to document the duration of the acute haemodynamic effects in patients with heart failure. Previous observations in hypertensive patients showed a significant effect still persisting two hours after a 10 mg oral dose. Further studies, moreover, should determine whether the observed haemodynamic changes persist during long-term treatment and if any undesirable effects are associated with drug dosages higher than those used in the treatment of angina pectoris.
We thank Dr William McKenna for reviewing the manuscript.
